Haemonetics is showing early signs of a turnaround, with Q1 FY2027 revenue up 5.6% YoY and gross margin expanding to 59.8%, the highest in recent quarters. However, the company's elevated leverage (D/E of 1.40) and persistent TTM revenue decline of 2.0% warran...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $1.14+5.6% vs $1.08 | $339M+3.5% vs $328M |
Q2 2026 May 7, 2026 | $1.29+0.8% vs $1.28 | $346M+2.8% vs $337M |
Q1 2026 Feb 5, 2026 | $1.31+3.1% vs $1.27 | $339M+2.1% vs $332M |
Q4 2025 Nov 6, 2025 | $1.27+13.4% vs $1.12 | $327M-0.7% vs $330M |
BOSTON, Sept. 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, November 5, 2026.
Femasys (NASDAQ: FEMY - Get Free Report) and Haemonetics (NYSE: HAE - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation. Risk and Volatility Femasys has a beta of -2.07, indicating
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Intellia Therapeutics NASDAQ: NTLA executives outlined plans for a potential launch of its hereditary angioedema treatment, lonvo-z, while discussing the company's ongoing Phase III program in transthyretin amyloidosis and its capital position during a Morgan Stanley event.
Benchmark HAE against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Haemonetics Corporation (HAE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $104.68 | $4.76B | 51.06 | -1.97% | 7.29% | 12.03% | — | |
| $124.12 | $5.49B | -6.13 | -34.61% | -39.58% | -31.83% | — | |
| $76.01 | $16.97B | 30.53 | 1.74% | 13.18% | 11.01% | — | |
| $126.45 | $4.29B | 43.75 | 7.57% | 6.97% | 7.43% | — | |
| $14.94 | $1.73B | -12.25 | 8.28% | -21.25% | -44% | — | |
| $0.64 | $44.25M | -0.55 | 15.4% | -747.19% | -94.35% | — |
Haemonetics Corporation (HAE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Haemonetics Corporation (HAE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 28, 2026·SEC
Jun 5, 2026·SEC
Get notified when HAE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Haemonetics Corporation (HAE) stock FAQ — growth, dividends, profitability & financials explained
Haemonetics Corporation (HAE) reported $1.35B in revenue for fiscal year 2026. This represents a 336% increase from $309.8M in 1997.
Haemonetics Corporation (HAE) saw revenue decline by 2.0% over the past year.
Yes, Haemonetics Corporation (HAE) is profitable, generating $96.3M in net income for fiscal year 2026 (7.3% net margin).
Haemonetics Corporation (HAE) has a return on equity (ROE) of 12.0%. This is reasonable for most industries.
Haemonetics Corporation (HAE) generated $291.2M in free cash flow for fiscal year 2026. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
